At close: December 13 at 4:00:02 PM EST
After hours: 7:59:27 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
10,480.0000
--
11,956.0000
4,335.0000
9,385.0000
Cost of Revenue
2,085.0000
--
2,019.0000
2,333.0000
3,280.0000
Gross Profit
8,395.0000
--
9,937.0000
2,002.0000
6,105.0000
Operating Expense
38,255.0000
--
44,352.0000
41,076.0000
27,409.0000
Operating Income
-29,860.0000
--
-34,415.0000
-39,074.0000
-21,304.0000
Net Non Operating Interest Income Expense
-589.0000
--
-12,723.0000
-10,055.0000
-8,135.0000
Other Income Expense
-7,877.0000
--
-1,257.0000
-3,471.0000
-4,370.0000
Pretax Income
-38,326.0000
--
-48,395.0000
-52,600.0000
-33,809.0000
Net Income Common Stockholders
-37,742.0000
--
-47,454.0000
-52,595.0000
-38,648.0000
Diluted NI Available to Com Stockholders
-37,742.0000
--
-47,454.0000
-52,595.0000
-38,648.0000
Basic EPS
20.20
-107.40
-2.17k
-5.16k
-13.50k
Diluted EPS
20.20
-107.40
-2.17k
-5.16k
-13.50k
Basic Average Shares
4,589.2720
384.4730
21.8580
10.1900
2.8620
Diluted Average Shares
4,589.2720
384.4730
21.8580
10.1900
2.8620
Total Operating Income as Reported
-30,231.0000
--
-34,415.0000
-40,708.0000
-26,647.0000
Rent Expense Supplemental
911.0000
--
629.0000
282.0000
690.0000
Total Expenses
40,340.0000
--
46,371.0000
43,409.0000
30,689.0000
Net Income from Continuing & Discontinued Operation
-37,742.0000
--
-47,454.0000
-52,595.0000
-33,809.0000
Normalized Income
-29,936.0000
--
-45,247.0000
-49,889.0000
-29,249.0000
Interest Expense
8,768.0000
--
12,723.0000
8,421.0000
2,792.0000
Net Interest Income
-589.0000
--
-12,723.0000
-10,055.0000
-8,135.0000
EBIT
-31,459.0000
--
-35,672.0000
-44,179.0000
-31,017.0000
EBITDA
-29,103.0000
--
-33,380.0000
-42,366.0000
-28,737.0000
Reconciled Cost of Revenue
2,085.0000
--
2,019.0000
2,333.0000
3,280.0000
Reconciled Depreciation
2,356.0000
--
2,292.0000
1,813.0000
2,280.0000
Net Income from Continuing Operation Net Minority Interest
-37,742.0000
--
-47,454.0000
-52,595.0000
-33,809.0000
Total Unusual Items Excluding Goodwill
-7,806.0000
--
-2,207.0000
-2,706.0000
-4,560.0000
Total Unusual Items
-7,806.0000
--
-2,207.0000
-2,706.0000
-4,560.0000
Normalized EBITDA
-21,297.0000
--
-31,173.0000
-39,660.0000
-24,177.0000
12/31/2020 - 5/12/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
TNXP Tonix Pharmaceuticals Holding Corp.
0.2405
+5.07%
CDIO Cardio Diagnostics Holdings, Inc.
1.2600
+5.00%
PALI Palisade Bio, Inc.
1.7700
-25.00%
EYEN Eyenovia, Inc.
0.0835
-4.79%
CERO CERo Therapeutics Holdings, Inc.
0.0567
-18.53%
ENTO Entero Therapeutics, Inc.
0.5839
-5.81%
BIOR Biora Therapeutics, Inc.
0.5597
0.00%
SONN Sonnet BioTherapeutics Holdings, Inc.
1.8100
+2.26%
OCGN Ocugen, Inc.
0.8574
+0.59%
SLXN Silexion Therapeutics Corp
3.5200
+5.39%